Olema Oncology, Inc. (OLMA) stock
Close on Nov 12, 2026Market cap $657.98MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $657.98M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.78
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$235.95M
- EPS, diluted
- -$2.36
- Book value per share
- $3.65
- Diluted shares
- 101M
Trading
- Next earnings
- Mar 15, 2027 (estimated, before the open)
- Previous close
- $8.04
- Open
- $7.88
- Day's range
- $7.45 – $8.02
- Volume
- 1,996,919
- Average volume (20 days)
- 1,438,241
- Index membership
- Russell 2000 (since Jun 2023), Russell 3000 (since Aug 2023)
- Beta (5 years)
- 1.64
- 52-week range
- $6.24 – $36.26
- RSI (14 days)
- 49.7
- Volatility (1 year)
- 154.2%
- Relative volume
- 1.72×
- WACC
- 13.1%
On 2 of our idea lists: More cash than they're worth, Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | OLMA | S&P 500 | Difference | OLMA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +2.2% | -2.7% | +4.9 pts | ||
| 3 months | -28.0% | -1.7% | −26.2 pts | ||
| Year to date | -69.9% | +11.9% | −81.8 pts | ||
| 1 year | -6.7% | +12.0% | −18.7 pts | ||
| 3 years | -52.5% | +78.2% | −130.7 pts | -22.0% | +21.2% |
| 5 years | -72.2% | +73.2% | −145.4 pts | -22.6% | +11.6% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Olema Oncology filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Update
- Update
- Results
About Olema Oncology
Pharmaceutical Preparations
Olema is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing targeted therapies for breast cancer and other hormone-driven cancers. The company's lead investigational candidate is palazestrant, an oral small molecule acting as a complete estrogen receptor antagonist and selective estrogen receptor degrader. Olema is advancing palazestrant in late-stage clinical trials both as a single agent and alongside approved targeted medicines for patients with advanced or metastatic breast cancer. A second clinical-stage candidate, OP-3136, functions as a selective inhibitor of KAT6 for breast cancer and other solid tumors. Olema does not currently have approved products or commercial sales, serving patients through clinical trials.
Company profile, executives and historyOlema Oncology stock: common questions
What is Olema Oncology's stock price?
OLMA closed at $7.52 on Nov 12, 2026, down 6.47% on the day. Over the past 52 weeks it traded between $6.24 and $36.26.
What is Olema Oncology's market cap?
Olema Oncology was worth $657.98M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is OLMA's P/E ratio?
Olema Oncology lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.36), so it has no meaningful P/E ratio.
Does Olema Oncology pay a dividend?
No. Olema Oncology has not paid a cash dividend over the last twelve months.
When does Olema Oncology report earnings next?
Olema Oncology is expected to report Q4 FY2026 results on Mar 15, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has OLMA stock performed over the past year?
Including dividends, OLMA returned -6.7% over the past year, against +12.0% for the S&P 500.
How many OLMA shares are sold short?
17M shares were sold short at the latest FINRA report, 36.05% of the float, or 11.9 days of average trading volume.
Who are Olema Oncology's competitors?
Companies most similar to Olema Oncology by business, industry and size include ATOS, ZNTL, CNTX, CRBP, SLS.
See a number that looks wrong?